Targeting FAP in human cancer patients with the humanized monoclonal antibody sibrotuzumab, which shows high affinity for binding to FAP [98], or the FAP enzyme inhibitor talabostat [99], which has not demonstrated clinical efficacy in NSCLC patients. The gene discussed is FAP; the disease is non-small cell lung carcinoma.